e-therapeutics to Present Preclinical Data on ETX-148 at EAHAD 2025
e-therapeutics has announced plans to present new preclinical data for ETX-148 at the Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) in February 2025. The presentation will showcase the efficacy and safety results of ETX-148 in murine models of haemophilia A and B. ETX-148, which is being developed for treating bleeding disorders, is currently in IND-enabling studies, with an IND submission planned for 2026.
The oral presentation, numbered OR10, will take place during the SLAM session on February 7th, 2025, at EAHAD 2025, which runs from February 4th to 7th.
e-therapeutics ha annunciato piani per presentare nuovi dati preclinici per ETX-148 al Congresso Annuale dell'Associazione Europea per l'Emofilia e i Disturbi Affini (EAHAD) nel febbraio 2025. La presentazione metter脿 in luce i risultati di efficacia e sicurezza di ETX-148 in modelli murini di emofilia A e B. ETX-148, che 猫 in fase di sviluppo per il trattamento dei disturbi emorragici, 猫 attualmente in studi di abilitazione IND, con una sottomissione IND prevista per il 2026.
La presentazione orale, numero OR10, avr脿 luogo durante la sessione SLAM il 7 febbraio 2025, all'EAHAD 2025, che si svolge dal 4 al 7 febbraio.
e-therapeutics ha anunciado planes para presentar nuevos datos precl铆nicos para ETX-148 en el Congreso Anual de la Asociaci贸n Europea de Hemofilia y Trastornos Afines (EAHAD) en febrero de 2025. La presentaci贸n mostrar谩 los resultados de eficacia y seguridad de ETX-148 en modelos murinos de hemofilia A y B. ETX-148, que se est谩 desarrollando para el tratamiento de trastornos hemorr谩gicos, se encuentra actualmente en estudios que habilitan el IND, con una presentaci贸n de IND prevista para 2026.
La presentaci贸n oral, n煤mero OR10, tendr谩 lugar durante la sesi贸n SLAM el 7 de febrero de 2025, en EAHAD 2025, que se llevar谩 a cabo del 4 al 7 de febrero.
e-therapeutics電� 2025雲� 2鞗� 鞙犽熃 順堨毎氤� 氚� 甏�霠� 歆堩櫂 順戫殞(EAHAD) 鞐半 雽�須岇棎靹� ETX-148鞐� 雽�頃� 靸堧鞖� 鞝勳瀯靸� 雿办澊韯半ゼ 氚滍憸頃� 瓿勴殟鞚� 氚滍憸頄堨姷雼堧嫟. 鞚措矆 氚滍憸鞐愳劀電� A順� 氚� B順� 順堨毎氤戩潣 毵堨毎鞀� 氇嵏鞐愳劀鞚� ETX-148鞚� 須姤瓿� 鞎堨爠靹� 瓴瓣臣毳� 氤挫棳欷� 瓴冹瀰雼堧嫟. ETX-148鞚� 於滍槇 鞛レ暊 旃橂毳� 鞙勴暣 臧滊皽 欷戩澊氅� 順勳灛 IND 鞀轨澑 欷�牍� 鞐瓣惮 欷戩澊氅�, 2026雲� 於滌嫓毳� 瓿勴殟頃橁碃 鞛堨姷雼堧嫟.
OR10鞙茧 氩堩樃臧� 毵り波歆� 甑憪 氚滍憸電� 2025雲� 2鞗� 7鞚� SLAM 靹胳厴 欷戩棎 臧滌禍霅橂┌, EAHAD 2025電� 2鞗� 4鞚茧秬韯� 7鞚缄箤歆� 歆勴枆霅╇媹雼�.
e-therapeutics a annonc茅 des plans pour pr茅senter de nouvelles donn茅es pr茅cliniques pour ETX-148 lors du Congr猫s Annuel de l'Association Europ茅enne de la H茅mophilie et des Troubles Associ茅s (EAHAD) en f茅vrier 2025. La pr茅sentation mettra en avant les r茅sultats d'efficacit茅 et de s茅curit茅 d'ETX-148 dans des mod猫les murins de l'h茅mophilie A et B. ETX-148, qui est en cours de d茅veloppement pour traiter les troubles de la coagulation, est actuellement dans des 茅tudes d'habilitation IND, avec une soumission IND pr茅vue pour 2026.
La pr茅sentation orale, num茅rot茅e OR10, aura lieu pendant la session SLAM le 7 f茅vrier 2025, lors de l'EAHAD 2025, qui se d茅roulera du 4 au 7 f茅vrier.
e-therapeutics hat Pl盲ne angek眉ndigt, neue pr盲klinische Daten f眉r ETX-148 auf dem Jahreskongress der Europ盲ischen Vereinigung f眉r H盲mophilie und verwandte St枚rungen (EAHAD) im Februar 2025 vorzustellen. Die Pr盲sentation wird die Wirksamkeits- und Sicherheitsresultate von ETX-148 in mausmodellen von H盲mophilie A und B vorstellen. ETX-148, das zur Behandlung von Blutungsst枚rungen entwickelt wird, befindet sich derzeit in IND-erlaubenden Studien, mit einer IND-Einreichung, die f眉r 2026 geplant ist.
Die m眉ndliche Pr盲sentation mit der Nummer OR10 findet w盲hrend der SLAM-Session am 7. Februar 2025 auf der EAHAD 2025 statt, die vom 4. bis 7. Februar l盲uft.
- ETX-148 is progressing through IND-enabling studies
- Company has preclinical data ready for presentation at major industry conference
- IND submission not expected until 2026, indicating lengthy development timeline ahead
LONDON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, announced today that it will present new preclinical data demonstrating efficacy and safety of ETX-148 in murine models of haemophilia A and B at the Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), 4th-7th February 2025. ETX-148 is being developed for the treatment of bleeding disorders and is currently progressing through IND-enabling studies, with an IND submission anticipated during 2026.
Presentation Details
Title: Efficacy and Safety of ETX-148 in Murine Models of Haemophilia A and B
Format: Oral Presentation
Presentation Number: OR10
Date: 7th February 2025
Session: SLAM
About e-therapeutics plc
e-therapeutics plc ("ETX") uniquely combines computation and RNAi to discover and develop life-transforming medicines. ETX's proprietary RNAi chemistry platform, GalOmic鈩�, enables generation of specific, potent, and durable siRNA therapeutics for effective silencing of novel gene targets in hepatocytes. The cutting-edge HepNet鈩� computational platform allows ETX to discover better medicines faster through generation of novel insights and increased automation across all stages of drug development. HepNet鈩� encompasses an extensive hepatocyte-specific knowledgebase and a suite of advanced AI-driven approaches which enable identification of novel gene targets, rapid target-indication assessment, and predictive in silico siRNA design. The Company has specialist expertise and a robust position in applying computation to biology. Its computational approaches have been extensively validated through generation of data from pipeline programs and successful drug discovery collaborations with biopharma companies, such as Novo Nordisk, Galapagos NV, and iTeos Therapeutics.
Leveraging the combined capabilities of HepNet鈩� and GalOmic鈩�, ETX is progressing a therapeutic pipeline of highly differentiated RNAi candidates across a variety of therapeutic areas with high unmet need. The Company has generated positive proof-of-concept data on preclinical assets in metabolic dysfunction-associated steatohepatitis (MASH), dry age-related macular degeneration (dry AMD), haemophilia, heart failure, and cardiometabolic disease, further validating its computationally enhanced approach to research and development. ETX is currently progressing its GalOmic鈩� therapies towards the clinic with its most developed assets, ETX-312 for MASH, ETX-148 for bleeding disorders, and ETX-407 for dry AMD, at the IND-enabling stage.
Press Contact
Investor Relations Contact
FAQ
What is the current development stage of ETX-148 (ETXPF)?
What conditions is ETX-148 (ETXPF) being developed to treat?
When will e-therapeutics present ETX-148 preclinical data at EAHAD 2025?
What type of data will be presented for ETX-148 (ETXPF) at EAHAD 2025?
